These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: The role of amino-terminal sequence of beta-endorphin and dynorphin in the determination of opiate receptor type selectivity.
    Author: Chang JK, Chang KJ.
    Journal: Life Sci; 1983; 33 Suppl 1():267-9. PubMed ID: 6141489.
    Abstract:
    Previous studies have shown that morphiceptin is a highly selective mu-receptor agonist. Recently we have obtained a more potent and stable analog, Tyr-Pro-NMePhe-D-Pro-NH2 (PL017). This peptide retains mu-receptor selectivity. beta-Endorphin is known to be a potent but non-selective opioid peptide for mu-, delta- and benzomorphan binding sites. Dynorphin is a putative kappa-agonist with significant affinity to mu-, delta- and benzomorphan binding sites in rat brain membranes. To understand the structural requirement for receptor type selectivity the enkephalin sequence of beta-endorphin and dynorphin was replaced by that of morphiceptin analog. Replacing the Met-enkephalin sequence of beta h-endorphin by PL017 yields a peptide highly selective for mu-binding sites. Substituting the Leu-enkephalin sequence of dynorphin-17 produces a peptide [PL017-dynorphin(6-17)] that retains high affinities for mu- and kappa-binding sites and has very low affinities for delta- and benzomorphan binding sites. These results suggest that a morphiceptin sequence at the amino-terminus of large opioid peptides can dictate mu-receptor selectivity. An enkephalin sequence at the amino-terminus of large opioid peptides seems to be required to retain high affinity for delta- and benzomorphan binding sites. The high affinity of PL017-dynorphin(6-17) for kappa-binding sites but not for benzomorphan binding sites suggests that benzomorphan sites of rat brain are not kappa-sites.
    [Abstract] [Full Text] [Related] [New Search]